PT-141 (Bremelanotide, Vyleesi)
Melanocortin-receptor agonist acting centrally on the desire-and-arousal pathway.
At a glance
What it is: Melanocortin-receptor agonist acting centrally on the desire-and-arousal pathway..
Primary research applications:
- Hypoactive sexual desire disorder (HSDD) — FDA-approved
- Erectile dysfunction (off-label and prior development)
- General libido and arousal research
Editorial summary: PT-141 is one of the few peptides commonly discussed in wellness contexts that holds genuine FDA approval (Vyleesi, 2019) backed by Phase 3 placebo-controlled trials. The evidence for the approved indication in premenopausal women with HSDD is solid; off-label use in men and for general libido enhancement is more loosely characterized but mechanistically plausible.
- Class / structure
- Synthetic cyclic heptapeptide; α-MSH analog
- Half-life
- ≈ 2.7 hours (plasma)
- First described
- 1990s (developed from Melanotan II research)
- Regulatory status
- FDA-approved (Vyleesi, 2019)
What is PT-141?
Bremelanotide (PT-141) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH). It was originally developed by Palatin Technologies as a nasal spray for erectile dysfunction, then reformulated as a subcutaneous injection for female sexual dysfunction. The FDA approved bremelanotide as Vyleesi in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women.[1]
Discovery and development
PT-141 originated from melanocortin research that began with Melanotan II (MTII) at the University of Arizona, where Hadley and Hruby's group studied MTII's surprising side effect on sexual arousal during tanning research in the 1980s. Palatin Technologies developed PT-141 as a focused successor — a cyclic heptapeptide engineered to retain melanocortin receptor activity while reducing the off-target pigmentation effects of MTII.
The compound was first developed as a nasal spray for erectile dysfunction, with promising Phase 2 results, before nasal delivery was discontinued and the program reformulated for subcutaneous injection in female sexual dysfunction. The pivotal RECONNECT Phase 3 trials supported FDA approval as Vyleesi in June 2019 for HSDD in premenopausal women.
Mechanism of action
PT-141 activates melanocortin receptors (primarily MC3R and MC4R) in the central nervous system. Unlike PDE5 inhibitors (sildenafil, tadalafil), which act on the peripheral vascular mechanism of erection, PT-141 acts centrally on the desire and arousal pathway. The downstream effect involves dopaminergic activity in the medial preoptic area of the hypothalamus.
The central mechanism is why PT-141 can affect both desire (libido) and arousal, not just mechanical erectile function, and why it can work in situations where PDE5 inhibitors alone don't fully address the underlying problem.
Pharmacokinetics
Bremelanotide is administered subcutaneously, on-demand, approximately 45 minutes before anticipated sexual activity. Peak plasma concentrations occur within ~1 hour, with elimination half-life around 2.7 hours. Maximum frequency in the FDA labeling is one dose per 24 hours and no more than eight doses per month. The relatively short half-life is consistent with on-demand use — chronic dosing has not been the development path.
What the research shows
The peer-reviewed literature on PT-141 is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Increases sexual desire in women with HSDD | Phase 3 RCTs (RECONNECT) | Supported |
| Improves erectile function in men | Historical nasal ED data supportive; discontinued for BP concerns | Supported |
| Works centrally, not just mechanically | Mechanism | Supported |
| Has no side effects | Nausea, flushing, and transient BP elevations are common | Unsupported |
| Causes skin darkening / new moles | Documented in a small percentage of users (MC1R cross-activity) | Supported |
| Produces pronounced rapid-onset libido changes | Consistent with central mechanism; common in user reports | Plausible |
Reported user experiences
How the research describes administration
FDA-approved route (Vyleesi): 1.75 mg subcutaneous injection in the abdomen or thigh, at least 45 minutes before anticipated sexual activity. Use should not exceed 8 doses per month per product labeling.
This page describes the approved dosing for reference. Refer to a prescribing physician.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
PT-141 is one of the better-validated 'wellness-space' peptides, with genuine Phase 3 data and FDA approval in a defined population. The mechanism is legitimate and the acute effects are often unmistakable to users. Limitations are not efficacy but tolerability (nausea is the dominant issue) and concerns about chronic dosing effects on skin pigmentation and blood pressure. For its approved indication in premenopausal women with HSDD, it's a reasonable pharmacologic option.
Frequently asked questions
Is PT-141 FDA-approved?
Yes. Bremelanotide (PT-141) is approved as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Approval was granted in June 2019.
Does PT-141 work for men?
Historical studies of an intranasal formulation showed efficacy in erectile dysfunction, including in men who didn't respond to sildenafil. The nasal product was not approved due to blood pressure concerns. Off-label subcutaneous use in men is common but not FDA-approved for that population.
How quickly does PT-141 work?
In the approved protocol, it's injected about 45 minutes before anticipated activity. User reports often describe effects within 1–4 hours, with peak activity in the first few hours.
What are the main side effects?
Nausea is by far the most common; in RECONNECT, it affected about 40% of users at some point. Flushing, headache, and small BP increases are also common. Skin pigmentation changes and new moles have been reported with repeated use.
Does PT-141 cause new moles?
Because PT-141 also activates MC1R (the melanin-stimulating receptor), darkening of existing skin and moles is documented, and some users report new pigmented lesions. Any new or changing mole should be evaluated by a dermatologist — this is general good practice but especially relevant with melanocortin-agonist exposure.
How is PT-141 different from Melanotan II?
Both activate melanocortin receptors, but PT-141 (bremelanotide) is a selective cyclic peptide with an FDA approval and well-characterized clinical profile. Melanotan II is an older, less-selective research compound with no regulatory approval anywhere, a harsher side-effect profile, and far stronger pigmentation effects.
Can women use PT-141 if they don't have HSDD?
Off-label use happens but is outside the approval. The label specifies premenopausal women with acquired, generalized HSDD — a specific clinical category. Casual use in women without sexual dysfunction isn't what the Phase 3 trials established.
Does PT-141 work for post-SSRI sexual dysfunction?
The mechanism is plausible since PT-141 acts centrally on dopaminergic pathways that SSRIs suppress. Small reports and case series are supportive; no large RCT has formally addressed this specific population.
Can PT-141 affect blood pressure?
Yes — transient small increases in systolic blood pressure and small decreases in heart rate have been documented. The magnitude is usually modest. FDA labeling recommends caution in uncontrolled hypertension.
Is grey-market PT-141 safe?
Vyleesi is an FDA-approved, quality-controlled product. Grey-market PT-141 is sold as a 'research chemical' of variable purity and identity. Injecting unregulated peptides carries risks that exist independently of the pharmacology.
References
- FDA Approval Package for Vyleesi (bremelanotide) — NDA 210557, June 21, 2019. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000TOC.cfm
- Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. https://pubmed.ncbi.nlm.nih.gov/31599847/
- Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016;12(3):325-37. https://pubmed.ncbi.nlm.nih.gov/27181790/
- Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51-9. https://pubmed.ncbi.nlm.nih.gov/14963471/